Literature DB >> 15123020

Time to treatment in prolonged seizure episodes.

John M Pellock1, Anthony Marmarou, Robert DeLorenzo.   

Abstract

Prompt intervention in seizure emergencies is critical to reducing morbidity and mortality risks associated with status epilepticus. To determine the need for wider education about the benefits of at-home treatment, we examined the time from seizure onset to initial treatment in a cohort of patients with epileptic seizures. The seizure database of patients admitted in the greater Richmond, Virginia, area during a 5-year period (1989-1994) was queried to extract time to seizure treatment. Records were available for 889 patients. Patients were divided into two subgroups: children (age < 16 years, 29.7% of the cohort) and adults. Time to seizure treatment varied broadly; only 41.5% of all patients received their first antiepilepsy drug within 30 minutes. Time to treatment did not significantly differ between age groups. This baseline study supports the need for patient education regarding seizure emergencies and wider availability of at-home treatment options to shorten time to seizure treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123020     DOI: 10.1016/j.yebeh.2003.12.012

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  17 in total

1.  Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study.

Authors:  Michael J Lamson; Diane Sitki-Green; Gerald L Wannarka; Michael Mesa; Paul Andrews; John Pellock
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Status Epilepticus in Children.

Authors:  K Behera; S Rana; M Kanitkar; M Adhikari
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Emergency management of febrile status epilepticus: results of the FEBSTAT study.

Authors:  Syndi Seinfeld; Shlomo Shinnar; Shumei Sun; Dale C Hesdorffer; Xiaoyan Deng; Ruth C Shinnar; Kathryn O'Hara; Douglas R Nordli; L Matthew Frank; William Gallentine; Solomon L Moshé; John M Pellock
Journal:  Epilepsia       Date:  2014-02-06       Impact factor: 5.864

4.  Time from convulsive status epilepticus onset to anticonvulsant administration in children.

Authors:  Iván Sánchez Fernández; Nicholas S Abend; Satish Agadi; Sookee An; Ravindra Arya; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Margie Ream; James Riviello; Robert C Tasker; Tobias Loddenkemper
Journal:  Neurology       Date:  2015-05-06       Impact factor: 9.910

Review 5.  Pathophysiology of convulsive status epilepticus.

Authors:  Iván Sánchez Fernández; Howard P Goodkin; Rod C Scott
Journal:  Seizure       Date:  2018-08-06       Impact factor: 3.184

Review 6.  Timing is everything: Where status epilepticus treatment fails.

Authors:  Chloe E Hill; Alomi O Parikh; Colin Ellis; Jennifer S Myers; Brian Litt
Journal:  Ann Neurol       Date:  2017-07-29       Impact factor: 10.422

Review 7.  Clinical practice: the treatment of acute convulsive seizures in children.

Authors:  Lieven Lagae
Journal:  Eur J Pediatr       Date:  2011-02-08       Impact factor: 3.183

8.  Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus.

Authors:  Laxmikant S Deshpande; Robert E Blair; Nisha Nagarkatti; Sompong Sombati; Billy R Martin; Robert J DeLorenzo
Journal:  Exp Neurol       Date:  2007-01-09       Impact factor: 5.330

9.  Factors related to delays in pre-hospital management of status epilepticus.

Authors:  Leena Kämppi; Harri Mustonen; Seppo Soinila
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

10.  Analysis of the delay components in the treatment of status epilepticus.

Authors:  Leena Kämppi; Harri Mustonen; Seppo Soinila
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.